TY - JOUR
T1 - Absence of prognostic significance of bcl-2 immunopositivity in non- small cell lung cancer
T2 - Analysis of 427 cases
AU - Anton, Rose
AU - Brown, Richard W.
AU - Younes, Mamoun
AU - Gondo, Margaret M.
AU - Stephenson, Mark A.
AU - Cagle, Philip T.
PY - 1997/1/1
Y1 - 1997/1/1
N2 - The bcl-2 gene product inhibits apoptosis and is thought to participate in oncogenesis. Association of bcl-2 immunopositivity with improved prognosis of non-small cell lung cancers (NSCLG) is controversial. Although two studies have reported better survival in bcl-2immunopositive NSCLCs, a third series has contradicted this finding. The authors studied a relatively larger case series involving 427 patients for whom detailed information on long-term follow-up was available to determine the prognostic significance of bcl-2 expression. The study included 252 adenocarcinomas (AC), 111 squamous cell carcinomas (SCG), and 64 large cell carcinomas (LC). After antigen retrieval, sections were immunostained using a monoclonal anti-bcl2 antibody (1:60, Clone 124, Dako) and the avidin-bintin complex technique. Staining was scored as positive or negative mad also on a semiquantitative scale as 0, low (<10%), moderate (10% to 75%), or extensive (>75%). Bcl-2 immunoreactivity was correlated with survival using the actuarial survival method, Kaplan- Meier method, and log-rank test and was not associated with statistically significant differences in survival for NSCLCs (P = .5537). Differences in survival remained insignificant even after NSCLCs were stratified for cell type, stage, or grade, singly or in combination. Therefore, using this method, bcl-2 immunopositivity does not appear to act as an independent prognostic indicator in NSCLCs.
AB - The bcl-2 gene product inhibits apoptosis and is thought to participate in oncogenesis. Association of bcl-2 immunopositivity with improved prognosis of non-small cell lung cancers (NSCLG) is controversial. Although two studies have reported better survival in bcl-2immunopositive NSCLCs, a third series has contradicted this finding. The authors studied a relatively larger case series involving 427 patients for whom detailed information on long-term follow-up was available to determine the prognostic significance of bcl-2 expression. The study included 252 adenocarcinomas (AC), 111 squamous cell carcinomas (SCG), and 64 large cell carcinomas (LC). After antigen retrieval, sections were immunostained using a monoclonal anti-bcl2 antibody (1:60, Clone 124, Dako) and the avidin-bintin complex technique. Staining was scored as positive or negative mad also on a semiquantitative scale as 0, low (<10%), moderate (10% to 75%), or extensive (>75%). Bcl-2 immunoreactivity was correlated with survival using the actuarial survival method, Kaplan- Meier method, and log-rank test and was not associated with statistically significant differences in survival for NSCLCs (P = .5537). Differences in survival remained insignificant even after NSCLCs were stratified for cell type, stage, or grade, singly or in combination. Therefore, using this method, bcl-2 immunopositivity does not appear to act as an independent prognostic indicator in NSCLCs.
KW - Bcl-2
KW - Immunohistochemistry
KW - Lung
KW - Non-small cell carcinoma
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=0030928745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030928745&partnerID=8YFLogxK
U2 - 10.1016/S0046-8177(97)90062-9
DO - 10.1016/S0046-8177(97)90062-9
M3 - Article
C2 - 9308733
AN - SCOPUS:0030928745
VL - 28
SP - 1079
EP - 1082
JO - Human Pathology
JF - Human Pathology
SN - 0046-8177
IS - 9
ER -